Hi jsbuser,Clyde and onto otIn answer to the original question I...

Hi jsbuser,Clyde and onto ot

In answer to the original question I have to admit that I don't know the definitive answer. I had taken it as a given that the license covered all areas and I had never considered it as anything less. However it has got me thinking and researching....but as I am away from home base I am a little limited in having access to research material.... But I have refreshed some information that is quite interesting....refer to Paterson Research Notes 7 May 2010 namely:

Eastlands appointed AFG Venture Group to advise commercialisation for ArTiMist....Karen Dado is principal adviser........not heard a lot about this for a while have we ?

Eastlands have commenced a WHO product per qualification that allows for multi market entry. .... Again not heard too much but gives a clue to multi markets.

91 % of people suffering malaria live in Africa....if Patersons are correct then we really on need to consider the African market don't we ?

Target price of 0.76 target SP on derisked commercialised basis.

There are 110 countries in Africa, Asia, The Americas and the Pacific Region affected by malaria and 44 of these countries are in Africa.

As I can't give the answer I will send a query to EMS for clarification.

Regards

kippax